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(39% vs 7%, P< 0.005), chronic renal failure (19% vs 4%, P< 0.001),
a known source of infection (85% vs 54% P< 0.05), Candida spp
(7% vs 0%, P< 0.01) or CoNS infections (15% vs 2%, P< 0.05),
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Abstract: Although hematogenous pyogenic spinal infections have
been related to hemodialysis (HD), catheter-related sepsis, and spor-
adically, to other nosocomial infections or procedures, in most recent
studies and reviews the impact of nosocomial infection as a risk factor
for vertebral osteomyelitis (VO) is not well established. The aim of our
study was to describe the risk factors, infectious source, etiology,
clinical features, therapy, and outcome of health care associated VO
(HCAVO), and compare them with community-acquired VO (CAVO)
cases.
A retrospective cohort study of consecutive patients with
hematogenous VO was conducted in our third-level hospital between
1987 and 2011. HCAVO was defined as onset of symptoms after
1 month of hospitalization or within 6 months after hospital dis-
charge, or ambulatory manipulations in the 6 months before the
diagnosis.
Over the 25-year study period, among 163 hematogenous
pyogenic VO, 41 (25%) were health care associated, a percentage
that increased from 15% (9/61) in the 1987–1999 period to 31%
(32/102) in the 2000–2011 period (P< 0.01). The presumed source
of infection was an intravenous catheter in 14 (34%), cutaneous
foci in 8 (20%), urinary tract in 7 (17%), gastrointestinal in
3 (7%), other foci in 3 (7%), and unknown in 6 (15%).
Staphylococcus aureus was the most frequently isolated micro-
organism (14 cases, 34%), followed by coagulase-negative
Staphylococci (CoNS) in 6 (15%), and Enterobacteriaceae in
6 (15%) cases.
Compared with CAVO cases, patients with HCAVO were older
(mean 66.0 SD 13.0 years vs 60.5 SD 15.5 years), had more underlying
conditions (73% vs 50%, P< 0.05), neoplasm/immunosuppressiona-Nieves Larrosa, uig, MD,
irante, MD
higher mortality (15% vs 6%, P¼ 0.069), and a higher relapse rate in
survivors (9% vs 1%, P< 0.05).
Presently, in our setting, one-third of hematogenous pyogenic VO
infections are health care associated, and a third of these are poten-
tially preventable catheter-related infections. Compared with CAVO,
in health care associated hematogenous VO, mortality and relapse
rates are higher; hence, further prevention measures should be
assessed.
(Medicine 94(3):e365)
Abbreviations: CAVO = community-acquired vertebral
osteomyelitis, CoNS = coagulase-negative staphylococci,
HCAVO = health care associated vertebral osteomyelitis, HD =
hemodialysis, IDRSAB = intravascular device related
Staphylococcus aureus bloodstream infection, IE = infective
endocarditis, IQR = interquartile range, MRSA = methicillin-
resistant S aureus, MSSA = methicillin-susceptible S aureus, SD =
standard deviation, UTI = urinary tract infection, VO = vertebral
osteomyelitis.
INTRODUCTION
S pontaneous hematogenous pyogenic vertebral osteomyelitis(VO) is an uncommon disease with an estimated incidence
of 0.2 to 2.4 cases per 100,000 population/y.1–20 Previously
described risk factors for VO are older age (incidence 6.5–9.8/
100,000 population/y), diabetes mellitus, malignancy, immu-
nosuppression, liver disease, end-stage renal failure, liver cir-
rhosis, intravenous drug use, and previous infection,
particularly bloodstream infection.1–10,21–24 Recently, spinal
infections have also been related to hemodialysis (HD),14,20,25
catheter-related sepsis,1,2,7,10,16,20,26 and sporadically, other
nosocomial infections or procedures.3,13–16,20,26
Most recent studies and reviews have not mentioned
nosocomial infection as a risk factor for VO. Nonetheless, in
a small series of 20 VO cases published 18 years ago, Torda
et al26 found that the infection was of nosocomial acquisition in
60% of patients, and a recent review has suggested that noso-
comial infection may have contributed to the increase in spinal
infections3. In our previous study10 and 1 by other authors,14
VO was considered nosocomial-acquired in around 19% of
cases. Available data on the impact, source of infection, clinical
findings, and outcome of health care associated hematogenous
spinal infections, however, are limited.
The aim of this study was to describe the risk factors,
infectious source, etiology, clinical features, therapy, and out-ssociated hematogenous pyogenic VO




Study Design, Patients, and Settings
In this retrospective review of all consecutive VO cases
diagnosed at Vall d’Hebron Hospital, a tertiary referral center
for complex vertebral surgery patients, patients with previous
spinal instrumentation or surgery, tuberculosis (n¼ 53),
brucellosis (n¼ 13), or no definitive bacteriological diagnosis
(n¼ 16) were excluded. All consecutive adult patients
(18 years) diagnosed with VO from January 1987 to Decem-
ber 2011 were enrolled. Patients were identified from our
infectious diseases department VO registry, and most of them
were followed-up by one of the authors (C.P.).
Data Collection
Demographic, clinical, diagnostic, treatment, and follow-
up data were obtained by chart abstraction and entered in a
database created specifically for the study. To assess the effec-
tiveness of antibiotic and surgical therapy, only survivor patients
followed-up for at least 1.5 years to detect relapses after therapy
completion were included.
Definitions
The diagnosis of hematogenous pyogenic VO was estab-
lished on previously published criteria,10 which include absence
of prior surgery, spinal instrumentation or contiguous VO, and
presence of 3 criteria: compatible clinical picture; consistent
imaging findings on computed tomography or magnetic reson-
ance imaging, or increased uptake on technetium bone scan;
isolation of pyogenic microorganisms in blood culture or
samples obtained by open surgery or percutaneous biopsy of
bone or adjacent tissues. Coagulase-negative Staphylococci
(CoNS) and other skin contaminants were considered true
pathogens only when isolated from a sterile bone biopsy in
at least 2 samples or in 2 or more blood cultures drawn on
separate occasions.
VO was considered health care associated according to
published criteria with some modifications.27 First, onset of
symptoms >1 month after hospitalization with no evidence of
VO at the time of admission; there is not a previously estab-
lished cutoff period for health care VO-associated designation;
all health care cases took at least a month for symptoms to
develop, or symptom onset within 6 months after discharge
(designated nosocomial VO). Second, ambulatory diagnostic or
therapeutic manipulations within 6 months before symptom
onset (designated nosohusial VO), including long-term central
venous catheter use, autologous or prosthetic arteriovenous
fistula for HD, invasive intravascular techniques (cardiac cathe-
terization, pacemaker insertion, other intravascular devices,
intravenous chemotherapy, or contrast administration), urolo-
gical, gynecological, or digestive procedures, and cutaneous
manipulations (eg, acupuncture, intramuscular injections).
Catheter-related bloodstream infection is defined else-
where.28 As to the presence of infective endocarditis (IE), only
patients with definite IE according to the modified Duke criteria
were included.
Renal failure was defined as serum creatinine 2 mg/dL.
Neurological complication was established on the presence of
motor deficits or meningitis.
Pigrau et alOutcome
Patients were clinically followed-up during hospitalization
and in the outpatient clinic. In-hospital mortality was defined as
2 | www.md-journal.comdeath by any cause during hospitalization. Related mortality
was defined as death secondary to sepsis, VO complications, or
IE in cases associated with this disease.
Treatment failure was defined based on the following:
infection-related death during hospitalization; persistent infec-
tion (clinical signs or persistently high acute-phase reactants
with no other inflammatory causes and isolation of the same
microorganism); or relapse, established on reappearance or
worsening of clinical signs and analyses after a period of
improvement, and isolation of the same microorganism. To
evaluate relapse, only patients followed-up for at least 1.5 years
after antibiotic therapy were included.
Statistical Analysis
Normally distributed quantitative variables are expressed
as the mean and standard deviation (SD) and those with skewed
distribution as median and interquartile range (IQR). Data for
discrete variables are expressed as percentages. Continuous
variables were compared using the unpaired Student t or
Mann–Whitney U test, and proportions using the x2 or Fisher
exact test, where appropriate. All statistical tests were 2-tailed,
and statistical significance was set at a P value of <0.05.
Statistical analyses were performed with Microsoft SPSS-
PCþ, 15.0 (SPSS, Chicago, IL).
Ethical Considerations
Because data collection began in 1987 and no direct patient
contact was planned, the requirement for informed consent
was waived.
RESULTS
Over the 25-year study period, hematogenous pyogenic
VO was diagnosed in 163 patients, and 41 cases (25%) were
health care associated. Percentage of HCAVO increased from
15% (9/61) in 1987–1999 to 31% (32/102) in 2000–2011
(P< 0.01).
Twenty-six (63%) HCAVO patients were men, with a
mean age of 66.3 years (SD 13.0). Mean age was similar in
the 2 periods (61.9 years [SD 14.8] vs 62.1 years [SD 15.3],
P¼ non significant). Twenty-nine of the 41 cases (71%) were
considered nosocomial (in all symptoms of VO started at least
1 month after hospital discharge) and 12 (29%) nosohusial.
Demographic data, clinical features, and laboratory results in
HCAVO cases are shown in Table 1.
Source of Infection
The infectious source was established in 35 (85%)
HCAVO cases (Table 2). The most important was catheter-
related infection in 14 (34%), 9 due to central venous catheters
and 5 due to peripheral venous catheters. Seven of these patients
had a previous documented catheter-related bloodstream infec-
tion due to the same microorganism isolated in VO, 4 patients
had previous phlebitis, 2 cases of Candida albicans infection
occurred in patients with previous parenteral nutrition and no
other Candida foci, and 1 renal transplant patient had well-
documented plasmocoagulase-negative VO, with no other
source of infection. Microbiological etiologies of catheter-
related VO are outlined in Table 2.
Medicine  Volume 94, Number 3, January 2015Overall, HCAVO was associated with an HD in 5/41 cases
(12%), all due to long-term catheter-related infection and none
secondary to an arteriovenous fistula.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.














1 M 66 6 NC Osteoarticular MSSA Yes No No Cured 120
2 F 66 5 NC Urinary tract Streptococcus
agalactiae
Yes Meningitis No Death —
3 M 77 3 NC Gastrointestinal Enterococcus
faecalis
Yes No No Cured 30
4 F 70 3 NC Cutaneous MRSA No No No Cured 36
5 F 57 2 NC Catheter (central) CoNS No No No Cured 30
6 F 72 2 NC Catheter (central) Candida glabrata Yes No No Cured 30
7 M 45 5 NC Unknown Pseudomonas
aeruginosa
No Deficit No Cured 30
8 F 76 2 NC Catheter (peripheral) MSSA No Meningitis No Death —
9 F 79 3 NC Catheter (peripheral) MSSA Yes No Yes Cured Relapse (1 mo)
10 M 67 5 NC Urinary tract Escherichia coli No No No Cured 30
11 F 71 3 NC Gynecological E faecalis No No No Cured 30
12 M 54 5 NC Unknown CoNS No Deficit Yes Cured 30
13 M 76 6 NC Catheter (central) Candida albicans No No No Cured Relapse (6 mo)
14 F 29 3 NC Cutaneous MSSA No No No Cured 36
15 M 81 5 NC Catheter (central) C albicans No No No Cured 24
16 F 66 6 NC Catheter (central) MRSA Yes Deficit No Cured Relapse (2 mo)
17 F 55 4 NC Catheter (central) MSSA No No No Death c
18 M 60 5 NC Catheter (peripheral) CoNS No Deficit No Cured 6 mo (death)
19 F 67 1 NC Cutaneous Propionibacterium
acnes
No No No Cured 84
20 M 59 2 NC Unknown CoNS No No No Death —
21 M 48 4 NC Cutaneous MSSA No Deficit Yes Cured 60
22 M 79 1.5 NC Urinary tract E coli No No No Cured 36
23 M 86 5 NC Urinary tract Enterobacter
cloacae
No Deficit No Cured 18
24 F 75 1.5 NC Respiratory P aeruginosa No No No Cured 7 mo (death)
25 M 57 4 NC Gastrointestinal Streptococcus
viridans group
No Deficit No Cured 72
26 M 73 3 NC Urinary tract E faecalis Yes No No Cured 30
27 M 61 4.5 NC Catheter (peripheral) CoNS No No No Cured 4 mo (death)
28 M 71 4 NC Unknown S agalactiae No No No Cured 18
29 M 81 1 NC Catheter (central) MRSA Yes No No Cured 18
30 M 59 NH Gastrointestinal Bacteroides
fragilis
No No No Cured 30
31 M 58 NH Catheter (peripheral) MSSA No No No Cured 36
32 M 80 NH Urinary tract E coli No Deficit No Death —
33 M 81 NH Catheter (central) MSSA No No No Death —
34 F 57 NH Unknown MSSA No No No Cured 36
35 M 81 NH Catheter (central) CoNS No No No Cured 24
36 M 81 NH Cutaneous Streptococcus
pyogenes
No No No Cured 18
37 M 74 NH Urinary tract E coli No Deficit No Cured 18
38 F 46 NH Unknown Achromobacter
xylosoxidans
No No No Cured 24
39 M 45 NH Cutaneous MSSA No Deficit Yes Cured 18
40 M 52 NH Cutaneous Klebsiella
pneumoniae
No Deficit No Cured 24
41 F 81 NH Cutaneous MSSA No No No Cured 18
CoNS¼ coagulase-negative Staphylococci, MRSA¼methicillin-resistant Staphylococcus aureus, MSSA¼methicillin-susceptible S aureus,
NC¼ nosocomial, NH¼ nosohusial, Previous hosp.¼ time since the previous hospitalization, VO¼ vertebral osteomyelitis.
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TABLE 2. Presumed Source of Infection in 41 Health Care








Other cutaneous foci 8 (20%)
Urinary tract manipulation/infection 7 (17%)
Gastrointestinal manipulation 3 (7%)
Other fociy 3 (7%)
Unknown 6 (15%)
HCAVO¼ health care associated VO, VO¼ vertebral osteomyelitis.
Staphylococcal 11 (methicillin-susceptible Staphylococcus aureus
5, methicillin-resistant S aureus 2, coagulase-negative Staphylococci 4),
Candida spp 3.
y
TABLE 3. Microorganisms Causing Health Care Associated
Pyogenic VO
Variable HCAVO, n¼ 41 (%)
Gram-positives 27 (65.8)




Streptococcus species 4 (9.8)
Streptococcus viridans 1 (2.4)
Streptococcus pyogenes 1 (2.4)
Streptococcus agalactiae 2 (4.9)
Enterococcus faecalis 3 (7.3)
Gram-negatives (aerobic) 9 (21.9)
Escherichia coli 4 (9.8)
Pseudomonas aeruginosa 2 (4.9)
Klebsiella pneumoniae 1 (2.4)
Enterobacter cloacae 1 (2.4)
Achromobacter xylosoxidans 1 (2.4)
Other
Candida albicans 2 (4.9)
Candida glabrata 1 (2.4)
Propionibacterium acnes 1 (2.4)
Bacteroides fragilis 1 (2.4)
CoNS¼ coagulase-negative Staphylococci, HCAVO¼ health care
associated VO, IE¼ infective endocarditis, MRSA¼methicillin-resist-
Pigrau et al Medicine  Volume 94, Number 3, January 2015Among the cutaneous foci, 1 had a previous streptococcal
cellulitis, 4 infected skin ulcers (2 Klebsiella spp, 1 methicillin-
susceptible Staphylococcus aureus [MSSA], and 1 methicillin-
resistant S aureus [MRSA]), and 4 skin abscesses (1 developed a
gluteus abscess after an intramuscular injection, and 12 weeks
later was diagnosed with S aureus HCAVO).
Among 7 cases related with previous urological foci, 5
were associated with urinary catheterization, 1 secondary to
urological surgery with a complicated postoperative urinary
tract infection (UTI), and 1 patient had recurrent UTI after
prostatic cancer surgery. Previous bacteriemic UTI was docu-
mented in only 1 urinary-related case.
There were 3 digestive-associated cases, 2 related with
esophageal manipulation, and 1 with a previous endoscopic
retrograde cholangiopancreatography study.
The osteoarticular-related case developed concomitant
bacteriemic S aureus HCAVO and prosthetic knee joint infec-
tion 6 months after the initial prosthetic procedure. The respir-
atory-related case was a Pseudomonas aeruginosa colonized
patient who developed P aeruginosa VO 1.5 months after
tracheal prosthesis manipulation.
Among the 12 nosohusial cases, 3 (25%) were considered
catheter-related, all of staphylococcal etiology.
Etiology
Blood cultures were positive in 29/40 (72.5%) patients
(Table 3). Bone samples in 22 patients isolated a microorganism
in 18 cases (diagnostic yield 82%), all concordant with the
blood culture isolate.
S aureus was the most frequently isolated microorganism
(14 cases, 34%), followed by CoNS and Enterobacteriaceae
(Table 3). There were 2 cases of anaerobic HCAVO. In 1,
caused by Bacteroides spp, the patient had an esophageal fistula
and developed VO after esophageal manipulation, whereas the
other patient had well-documented Propionibacterium acnes
VO (3 positive biopsy samples) 1 month after cardiac cathe-
terization.
Catheter-associated HCAVO cases were due to staphylo-
Gynecological in 1 (hysterectomy with postoperative surgical infec-
tion), respiratory in 1, and osteoarticular in 1.cocci (n¼ 11) or Candida spp (n¼ 3), and urinary tract
related cases were mainly due to gram-negative microorgan-
isms (n¼ 5/7).
4 | www.md-journal.comComparison Between HCAVO and CAVO
The characteristics of patients with HCAVO and CAVO
are presented in Table 4. Patients with HCAVO were older and
underlying diseases were more frequent than in the CAVO
group, particularly malignancy/immunosuppressive treatment
and chronic renal failure, whereas intravenous drug use was
associated with CAVO. Of note, malignant disease and immu-
nosuppressor treatment were significantly higher in patients
diagnosed after 1999 (23 [22.5%] vs 2 [3.3%], P¼ 0.001).
Among these 25 patients, 20 had an active neoplasm and 5
received immunosuppressors for a solid transplant or a systemic
disease.
Median diagnostic delay was similar in the 2 groups. The
source of infection was established in 85% of HCAVO, whereas
in CAVO, the source was unknown in nearly half the cases.
Catheter-related infection was the most frequent source in
HCAVO, whereas UTI was the most common origin in CAVO
patients. As was expected, there were a higher percentage of
infections due to CoNS and Candida spp in the HCAVO group,
mainly associated with well-documented catheter-related infec-
tions.
Back pain and fever were the most common symptoms,
with back pain being less frequent in HCAVO. Among 5
HCAVO patients who did not present back pain, the clinical
presentation was persistent fever in 4 (2 persistent bloodstream
infection), and the diagnosis of VO was established after
excluding IE and other infectious foci.
ant Staphylococcus aureus, MSSA¼methicillin-susceptible S aureus,
VO¼ vertebral osteomyelitis.Overall, IE was diagnosed in 8/41 (20%) patients, and 8/27
(30%) gram-positive HCAVO; none of the gram-negative
HCAVO had IE. Four of the 14 patients (29%) with
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Univariate Comparison Between 41 Patients With Health Care Associated Hematogenous Pyogenic VO (HCAVO) and
122 Patients With CAVO
Variable Demographic Data HCAVO Group (n¼ 41) CAVO Group (n¼ 122) OR (95% CI) P Value
Age, median y (SD) 66.32 (13.0) 60.54 (15.5) 1.03 (1.002–1.06) 0.033
Male sex 27 (65.9) 81 (66.4) 0.98 (0.46–2.06) 0.95
Underlying conditions 30 (73.2) 61 (50.0) 2.73 (1.25–5.93) 0.01
Diabetes mellitus 13 (31.7) 37 (30.3) 1.07 (0.50–2.29) 0.87
Neoplasm or immunosuppressors 16 (39.0) 9 (7.4) 8.0 (3.19–20.26) <0.001
Liver cirrhosis 4 (9.8) 25 (20.5) 0.42 (0.14–1.29) 0.12
Chronic renal failure 8 (19.5) 5 (4.1) 5,67 (1.74–18.50) 0.002
Intravenous drug user 0 (0) 10 (8.2) 1.37 (1.24–1.5) 0.06
Source of infection
Catheter related 14 (34.2) 0 (0) 5.52 (3.92–7.76) <0.001
Skin and soft tissue 8 (19.5) 25 (20.5) 0.94 (0.39–1.29) 0.89
Urinary tract 7 (17.1) 31 (25.4) 0.60 (0.24–1.50) 0.27
Gastrointestinal 3 (7.3) 5 (4.1) 1.85 (0.42–8.09) 0.41
Other foci 3 (7.3) 5 (4.1) 1.85 (0.42–8.09) 0.41
Unknown 6 (14.6) 56 (45.9) 0.2 (0.08–0.51) <0.001
Etiology
MSSA 11 (26.8) 46 (37.7) 0.61 (0.28–1.32) 0.206
MRSA 3 (7.3) 3 (2.5)z 3.13 (0.61–16.17) 0.153
CoNS 6 (14.6) 2 (1.6) 10.29 (1.99–53.24) 0.001
Streptococcus spp

7 (17.1) 37 (30.3) 0.47 (0.19–1.16) 0.098
Enterococcus faecalis 3 (7.3) 5 (4.1) 2.28 (o.68–7.63 0.171
Enterobacteriaceae 6 (14.6) 29 (23.8) 0.55 (0.21–1.44) 0.218
Other gram-negative 3 (7.3) 3 (2.5) 3.1 (0.61–16.17) 0.153
Candida spp 3 (7.3) 0 (0) 4.21 (3.2–5.56) 0.003
Clinical features
Diagnosis delay in days, median (IQR) 28 (13–56) 28 (8.5–45) 1.00 (0.99–1.01) 0.904
Back pain 36 (87.8) 120 (98.4) 0.12 (0.02–0.64) 0.004
Fever 30 (73.2) 95 (77.9) 0.77 (0.34–1.75) 0.54
Neurological complications 13 (31.7) 30 (24.6) 1.42 (0.65–3.09) 0.37
Neurological deficit 11 (26.8) 26 (21.3) 1.33 (0.6–3.01) 0.47
Meningitis 2 (4.9) 7 (5.7) 0.84 (0.17–4.23) 0.83
IE 8 (19.5) 28 (23) 0.81 (0.34–1.96) 0.65
Vertebral level involved
Cervical 8 (19.5) 16 (13.1) 1.60 (0.63–4.1) 0.32
Thoracic 13 (31.7) 25 (20.5) 1.80 (0.82–3.97) 0.14
Lumbar 15 (36.6) 75 (61.5) 0.36 (0.17–0.75) 0.006
Multifocal levels 5 (12.2) 6 (4.9) 2.68 (0.77–9.32) 0.11
Laboratory data
Blood culture (positive) 29/40 (72) 89/119 (75) 0.89 (0.40–1.99) 0.78
ESR (mean, mm/h) 75 (59–73) 94 (76–106) 0.07 (0.96–0.99) 0.03
Leukocytes 9800 (7950–13600) 12000 (9200–17700) 1 (0.99–1.00) 0.451
Therapy
Treatment duration, median, wk (IQR) 8 (6–10) 8 (6–9) 1 (0.98–1.01) 0.983
Hospitalization, median, d (IQR) 31 (19–50) 33 (22–47) 1.002 (0.99–1.01) 0.762
Vertebral surgery 4 (9.8) 16 (13.1) 0.71 (0.22–2.28) 0.57
Outcome
Mortality (related) 6 (14.6) 7 (5.7) 2.82 (0.89–8.93) 0.069
Relapse 3/32 (9.4) 1/109 (0.9) 10.45 (1.05–104) 0.015
Treatment failurey 9/41 (22) 8/122 (6.6) 3.98 (1.34–11.79) 0.008
Residual neurological deficitjj 5/35 (14.3) 11/115 (9.6) 1.58 (0.5–4.9) 0.43
Unfavorable outcome§ 12/41 (29.3) 19/122 (15.6) 2.24 (0.98–5.15) 0.053
CAVO¼ community-acquired VO, CI¼ confidence interval, CoNS¼ coagulase-negative Staphylococci, ESR¼Erythrocyte sedimentation rate,
HCAVO¼ health care associated VO, IE¼ infective endocarditis, IQR¼ interquartile range, MRSA¼methicillin-resistant Staphylococcus aureus,
MSSA¼methicillin-susceptible S aureus, OR¼ odds ratio, VO¼ vertebral osteomyelitis.
Including E faecalis.
yDeath or relapse.
z 2 Cases with previous community-acquired MRSA recurrent skin abscesses and 1 patient without known risk factors for community or hospital-
acquired MRSA.
§ Unfavorable outcome: death, relapse, or residual neurological deficit.
jjResidual neurological deficit is defined as persistence of the deficit after surgery and/or antibiotic therapy.
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catheter-related HCAVO had IE. Nevertheless, the percentage
of IE was similar in HCAVO and CAVO cases.
Neurological complications were observed in nearly one-
third of HCAVO, a percentage slightly higher than in CAVO
cases. In HCAVO, 27% of patients had a neurological deficit
and 2 had meningitis (5%). Three patients required spinal
surgery because of paraplegia. The incidence of neurological
complications in S aureus HCAVO was similar to non-S aureus
infections, 4/14 (29%) versus 9/27 (33%).
As to treatment, empirical antibiotics were started only in
patients with suspected bloodstream infection, with adjustment
according to the susceptibility pattern of isolated bacteria.
HCAVO cases were treated for a median of 8 weeks (IQR
6–9 weeks). IE patients received 4 to 8 weeks of intravenous
therapy according to the isolated microorganism; 2 patients
required further oral therapy due to paravertebral abscesses.
Non-IE cases were treated for a median of 8 weeks (IQR 6–10
weeks), within which there were 4 weeks of oral therapy (IQR
2–6 weeks). Five patients, with gram-negative VO, were treated
orally alone.
Spinal surgery was performed in 4/41 (10%) cases: in 3
patients because of neurological complications (paraplegia) and
in 1 with persistent fever to drain a large paravertebral abscess.
HCAVO patients required lengthy hospitalization (around
1 month), but duration was not longer than in CAVO cases. Six
HCAVO patients died during admission (15%). Death was
infection-related in all, and 3 patients had S aureus sepsis.
Among 35 patients who survived hospitalization and
underwent outpatient follow-up, 3 died of their underlying
disease in the first 7 months, and the remaining 32 had long-
term follow-up (median 30 months, IQR 20–42 months). In this
group, 3 (9%) relapsed, and 2 of them ultimately died due to the
infection: 1 with C albicans HCAVO treated with 8 weeks of
fluconazole who relapsed 6 months later and 1 with MSSA VO
and concomitant IE treated with cloxacillin for 6 weeks who
relapsed 1 month later. The third patient, a catheter-related
MRSA HCAVO with IE and a paravertebral abscess, that could
not be drained because of surgical contraindications, was
treated with vancomycin for 8 weeks and orally with cotrimox-
azole/rifampin for 8 weeks, and relapsed 2 months after com-
pleting therapy. She was treated with linezolid and relapsed
again, and finally cured after 6-month therapy with teicoplanin
and rifampin (follow-up 5 years).
Treatment duration and hospital stay were similar in the 2
groups, but HCAVO had a higher percentage of treatment
failures and a trend to higher mortality (15% vs 6%,
P¼ 0.069) and relapses (9% vs 1%, P¼ 0.015).
DISCUSSION
The results of our study show that nosocomial infection is
now a common source of hematogenous pyogenic VO in our
setting. One-third of these infections were catheter-related and
potentially preventable. Compared with CAVO, health care
related hematogenous VO was associated with higher mortality
and relapse rates. In our earlier experience (1987–1999), 15%
of VO cases were HCAVO, whereas our more recent data
(2000–2011) show that nearly one-third of spinal infections
are health care associated. The high incidence of HCAVO
contrasts with findings from previous studies, with reported
rates of 19%.10,14 Several factors could contribute to this higher
Pigrau et alincidence: first, our hospital is a referral center for complicated
spinal infections, and these are more common in patients with
underlying diseases, as was seen in our HCAVO cases; second,
6 | www.md-journal.comthe use of diagnostic and therapeutic techniques (outpatient
parenteral nutrition and HD) has considerably increased; third,
there is a high index of suspicion in our attending physicians,
based on a detailed history of previous admissions and health
care procedures, particularly those with a risk of bloodstream
infection.
Although an increase in the aging of the population and
immunosuppression may have had an influence on the higher
incidence of VO in recent years, age was similar (61.9 vs 62.1
years) in the 2 study periods in our series, but the incidence of
underlying immunosuppressive diseases was higher in the
second period. Thus, in our opinion, health care associated
infections and malignancy/immunosuppression are now the
most important factors that contribute to an increase in the
overall incidence of VO in the population.
The most common infectious source was a previous
catheter-related infection (one-third of cases), a percentage
similar to the 40% (33/83) we found in patients with health
care associated IE27 and lower than the 46% (148/319) of health
care associated bloodstream infections.28 Although our group
follows the guidelines for catheter-related bloodstream infec-
tions, new VO cases still occur. These data indicate the need to
improve the care in all steps provided to patients with intra-
vascular devices and to strictly follow the therapeutic guidelines
for catheter-related bloodstream infection, especially regarding
septic complications in S aureus infection.29,30
In other recent studies, VO has also been associated with
HD therapy.14,20,25 In our experience, this was the source of
infection in 12% of HCAVO and 3% of all VO cases, similar to
the 4% recently reported14 and <18% reported by Bhavan
et al.20 The percentage of VO in HD patients is not known,
although it is estimated that 1.3% of HD patients with blood-
stream infection will develop this complication31 and an inci-
dence of 1 episode every 215 patient-years has been reported.32
In our patients, no VO cases were associated with arteriovenous
fistula infection, in accordance with previous findings of a 3-
fold higher incidence in patients dialyzed with tunneled central
venous catheters than in those with arteriovenous fistulae.32
Mortality in this subset of patients is high, at 11% to 46%.25,32
Thus, it is crucial to reinforce preventive measures and provide
prompt diagnosis and treatment.
S aureus was the most commonly isolated microorganism,
especially in catheter-related cases. In 2 large series, VO was a
complication of S aureus bloodstream infection in 1.7% (146/
8739 cases)33 and 3% (22/724 cases)34 of patients. In our
previous study of S aureus bloodstream infection, 2/146
(1.2%) hospital-acquired cases had an osteoarticular source
of infection and in both patients, it was VO.35 The risk of
VO in patients with intravascular device related S aureus
bloodstream infection (IDRSAB) is similar, around 2.2% (7/
324 cases),36 although the study did not establish whether VO
was a direct consequence of IDRSAB or secondary to con-
comitant IE. In our study, only 21.4% of catheter-related
HCAVO had IE, thus, VO was likely a direct consequence
of catheter infection in most cases. The high risk of this
complication in patients with nosocomial IDRSAB has practical
implications. We believe that radiological imaging should be
performed to exclude VO in all patients with a previous
IDRSAB and new-onset or increased back pain.
From the clinical viewpoint, it is remarkable that back
pain, which is almost always present in VO, was absent in 12%
Medicine  Volume 94, Number 3, January 2015of HCAVO cases in our experience10 and in 14% in a large
review.2 These patients had persistent fever or bloodstream
infection after adequate antibiotic therapy of the underlying
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
infection, and the diagnosis of VO was ultimately established
after excluding other infectious foci (eg, IE and spleen abscess).
The percentage of IE in spontaneous pyogenic HCAVO
was high (19%) and similar to CAVO cases. As we reported
previously, this high incidence is attributable to our hospital
being a referral center for IE and a high index of clinical
suspicion.10 The high rate has practical implications and
suggests that conversion to early oral therapy should be avoided
until IE has been excluded, at least when it is clinically
suspected and in gram-positive infections.1,3,10
As our group observed in health care associated IE,27
HCAVO also affects elderly people with underlying conditions.
This comorbid status leads to close contact with the health
system and a higher risk of acquiring bloodstream infection,
IE, and VO, and it could have an influence on the prognosis of
the disease.
In comparison with CAVO, HCAVO cases had higher
mortality (15% vs 6%) and surviving patients a higher relapse
rate (9% vs 1%) in our study. Although, to a certain extent, these
findings may be related to the higher incidence of underlying
conditions in HCAVO, difficult to treat microorganisms, such as
Candida spp and MRSA, and in 1 case, the fact that surgical
drainage of a large abscess was unfeasible due to the patient’s
poor general condition may have influenced the higher mortality
rate.
As in all retrospective studies, there is a potential for bias and
statistical imprecision. It is possible that in the earlier period,
contact with the health care system was overlooked in some
patients and they were misclassified as CAVO, although this
would have increased the incidence of health care associated
cases. Our study has the referral bias of a large tertiary teaching
center with an IE and spinal surgery unit, which may have had an
impact on the rate of IE cases and neurological complications.
Echocardiography was not mandatory in enterobacterial infec-
tions, but the uncommon implication of this microorganism in IE
leads us to believe that IE rates would not have changed sub-
stantially if it had been performed. Extrapolation of the results to
other community hospitals should be done with caution. Detec-
tion of VO in pluripathological-hospitalized patients requires a
high index of suspicion, and some HAVO cases may have been
missed in severely ill patients. Nonetheless, our infectious dis-
eases department is highly aware of this disease, and most cases
are seen by the same staff member, a fact that would help
minimize elements of bias.
In conclusion, in our institution, one-third of current
hematogenous pyogenic VO infections are health care associ-
ated cases and a third of these are catheter-related infections,
and therefore, potentially preventable. HCAVO affects elderly
people with underlying conditions and is associated with higher
mortality and relapse rates than CAVO. Maximizing aseptic
measures before and during any invasive procedure (especially
those related to intravascular catheters) could reduce the inci-
dence of this condition.
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